Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Haneesha Mohan

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
The Lancet. HIV|August 7, 2023
Metabolic implications and safety of dolutegravir use in pregnancyValeriya Dontsova, Haneesha Mohan, Camille Blanco, et al.
Iscience|August 30, 2021
Vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired β-cell functionDana Al Rijjal, Ying Liu, Mi Lai, et al.
Diabetologia|January 16, 2019
The discovery of novel predictive biomarkers and early-stage pathophysiology for the transition from gestational diabetes to type 2 diabetesSaifur R Khan, Haneesha Mohan, Ying Liu, et al.
Diabetes|February 14, 2018
Elevated Medium-Chain Acylcarnitines Are Associated With Gestational Diabetes Mellitus and Early Progression to Type 2 Diabetes and Induce Pancreatic β-Cell DysfunctionBattsetseg Batchuluun, Dana Al Rijjal, Kacey J Prentice, et al.
Diabetologia|February 9, 2019
Correction to: The discovery of novel predictive biomarkers and early-stage pathophysiology for the transition from gestational diabetes to type 2 diabetesSaifur R Khan, Haneesha Mohan, Ying Liu, et al.
The Journal of Infectious Diseases|July 15, 2025
Fetal Defects in Mice Treated with Integrase Strand Transfer Inhibitors: Comparison of Dolutegravir, Raltegravir, Bictegravir and CabotegravirHaneesha Mohan, Jessica Nguyen, Audrey Yee, et al.
The Journal of Infectious Diseases|September 20, 2022
Second-Generation Human Immunodeficiency Virus Integrase Inhibitors Induce Differentiation Dysregulation and Exert Toxic Effects in Human Embryonic Stem Cell and Mouse ModelsMarie-Soleil R Smith, Haneesha Mohan, Abhinav Ajaykumar, et al.
Endocrinology|December 17, 2021
Hypothalamic miR-1983 Targets Insulin Receptor β and the Insulin-mediated miR-1983 Increase Is Blocked by MetforminJennifer A Chalmers, Prasad S Dalvi, Neruja Loganathan, et al.
Ebiomedicine|December 20, 2020
Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levelsHaneesha Mohan, Monica Guzman Lenis, Evelyn Y Laurette, et al.
Ebiomedicine|August 16, 2023
Folate deficiency increases the incidence of dolutegravir-associated foetal defects in a mouse pregnancy modelHaneesha Mohan, Jessica Nguyen, Ben MacKenzie, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
The Lancet. HIV|August 7, 2023
Metabolic implications and safety of dolutegravir use in pregnancyValeriya Dontsova, Haneesha Mohan, Camille Blanco, et al.
Iscience|August 30, 2021
Vascepa protects against high-fat diet-induced glucose intolerance, insulin resistance, and impaired β-cell functionDana Al Rijjal, Ying Liu, Mi Lai, et al.
Diabetologia|January 16, 2019
The discovery of novel predictive biomarkers and early-stage pathophysiology for the transition from gestational diabetes to type 2 diabetesSaifur R Khan, Haneesha Mohan, Ying Liu, et al.
Diabetes|February 14, 2018
Elevated Medium-Chain Acylcarnitines Are Associated With Gestational Diabetes Mellitus and Early Progression to Type 2 Diabetes and Induce Pancreatic β-Cell DysfunctionBattsetseg Batchuluun, Dana Al Rijjal, Kacey J Prentice, et al.
Diabetologia|February 9, 2019
Correction to: The discovery of novel predictive biomarkers and early-stage pathophysiology for the transition from gestational diabetes to type 2 diabetesSaifur R Khan, Haneesha Mohan, Ying Liu, et al.
The Journal of Infectious Diseases|July 15, 2025
Fetal Defects in Mice Treated with Integrase Strand Transfer Inhibitors: Comparison of Dolutegravir, Raltegravir, Bictegravir and CabotegravirHaneesha Mohan, Jessica Nguyen, Audrey Yee, et al.
The Journal of Infectious Diseases|September 20, 2022
Second-Generation Human Immunodeficiency Virus Integrase Inhibitors Induce Differentiation Dysregulation and Exert Toxic Effects in Human Embryonic Stem Cell and Mouse ModelsMarie-Soleil R Smith, Haneesha Mohan, Abhinav Ajaykumar, et al.
Endocrinology|December 17, 2021
Hypothalamic miR-1983 Targets Insulin Receptor β and the Insulin-mediated miR-1983 Increase Is Blocked by MetforminJennifer A Chalmers, Prasad S Dalvi, Neruja Loganathan, et al.
Ebiomedicine|December 20, 2020
Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levelsHaneesha Mohan, Monica Guzman Lenis, Evelyn Y Laurette, et al.
Ebiomedicine|August 16, 2023
Folate deficiency increases the incidence of dolutegravir-associated foetal defects in a mouse pregnancy modelHaneesha Mohan, Jessica Nguyen, Ben MacKenzie, et al.
Pageof 3